Active ingredientGlecaprevirCat. No. P-G037-001CAS 1365970-03-1Family · Pharmaceutical analytical standards
Glecaprevir
An NS3/4A protease inhibitor of the hepatitis C virus, used in a fixed combination with pibrentasvir. Approved in 2017 in the United States and Europe, it is active against all virus genotypes, 1 to 6. This family brings together the active ingredient and other impurities.
Did you know?It was the first eight-week treatment approved for all genotypes 1 to 6, in treatment-naive adults without cirrhosis: earlier regimens lasted 12 weeks or more.
Go to the active ingredient →Active ingredientGlecaprevirCat. No. P-G037-001CAS 1365970-03-1
ImpurityGlecaprevir Impurity 1 HydrochlorideCat. No. P-G037-004CAS 1360828-80-3
ImpurityGlecaprevir Impurity 2Cat. No. P-G037-006No product matches your search.
Need a molecule you cannot find?
Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.